{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:16:16Z","timestamp":1790043376742,"version":"4.0.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K08 DK118120"],"award-info":[{"award-number":["K08 DK118120"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K08 HL116952"],"award-info":[{"award-number":["K08 HL116952"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA233610"],"award-info":[{"award-number":["R01 CA233610"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The objective of this case cohort study was to describe our experience in the care of patients with immune checkpoint inhibitor\u2013related acute interstitial nephritis (ICI-AIN) including rechallenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A descriptive case series of patients that received an ICI and had an AKI (defined as a \u22651.5-fold increase in serum creatinine) as an immune-related adverse event (irAE), with biopsy-proven or clinically suspected ICI-AIN from January 1, 2014 to December 1, 2018 at Mayo Clinic, Rochester. We studied details regarding diagnosis, clinical course, management, and outcomes of rechallenge of immunotherapy. Complete response (CR) was defined as return of kidney function back to baseline or &lt;0.3 mg\/dl above baseline creatinine; partial response (PR) was defined as creatinine &gt;0.3 mg\/dl from baseline, but less than twofold above the baseline by the end of steroid course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 14 cases of biopsy-proven (35%) or clinically suspected (65%) ICI-AIN was identified. All patients had their ICI withheld and 12 patients received steroids. Steroid regimens were highly variable. The starting equivalent dose of prednisone was higher in those that had a CR versus a PR (median 0.77 mg\/kg versus 0.66 mg\/kg). Proton pump inhibitors (PPIs) were used in 11 patients and were stopped in eight (73%) patients at the time of the AKI event. A CR was seen in five (63%) of the eight patients who discontinued PPIs. Rechallenge was attempted in four of the 14 patients: three were successful with no recurrence of AKI, but one patient had recurrent AKI and fatal pneumonitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Careful review, withholding ICI and concomitant known AIN-inducing medications, along with prompt initial steroid management were the key in complete renal kidney recovery. A kidney biopsy should be strongly considered. Rechallenge of immunotherapy after a kidney irAE, although challenging, is possible and would need careful evaluation on an individual basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Podcast<\/jats:title>\n                    <jats:p>This article contains a podcast at https:\/\/www.asn-online.org\/media\/podcast\/K360\/2020_01_30_KID0000152019.mp3<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000152019","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T18:20:47Z","timestamp":1582050047000},"page":"16-24","source":"Crossref","is-referenced-by-count":69,"title":["Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy"],"prefix":"10.34067","volume":"1","author":[{"given":"Sandhya","family":"Manohar","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranine","family":"Ghamrawi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Chengappa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nazareth Hospital, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-6856","authenticated-orcid":false,"given":"Busra N. Bacik","family":"Goksu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Texas Southwestern, Dallas, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kottschade","sequence":"additional","affiliation":[{"name":"Departments of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Finnes","sequence":"additional","affiliation":[{"name":"Pharmacy, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Dronca","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[{"name":"Departments of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Cardiology, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma [published correction appears in N Engl J Med 379: 2185, 2018]","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma [published correction appears in N Engl J Med 377: 1345\u20131356, 2017]","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"B3-20230821","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol 29(suppl 4): iv264\u2013iv266, 2018]","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMc0904283","article-title":"Anti-CTLA4 antibody-induced lupus nephritis","volume":"361","author":"Fadel","year":"2009","journal-title":"N Engl J Med"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrneph.2010.71","article-title":"Drug-induced acute interstitial nephritis","volume":"6","author":"Perazella","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B9-20230821","first-page":"97","article-title":"Allergic interstitial nephritis: Clinical features and pathogenesis","volume":"66","author":"Cameron","year":"1988","journal-title":"Q J Med"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ndt\/gfu326","article-title":"Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury","volume":"30","author":"Praga","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5414\/CN10838","article-title":"Acute interstitial nephritis - a reappraisal and update","volume":"82","author":"Raghavan","year":"2014","journal-title":"Clin Nephrol"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2014.04.027","article-title":"Biopsy-proven acute interstitial nephritis, 1993-2011: A case series","volume":"64","author":"Muriithi","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ckj\/sfy100","article-title":"Renal toxicities associated with pembrolizumab","volume":"12","author":"Izzedine","year":"2019","journal-title":"Clin Kidney J"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: A report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B18-20230821","first-page":"8408015","article-title":"Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy","volume":"2018","author":"El Bitar","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"B19-20230821","article-title":"A new expression of immune checkpoint inhibitors\u2019 renal toxicity: When distal tubular acidosis precedes creatinine elevation","author":"Charmetant","year":"2019","journal-title":"Clin Kidney J"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","article-title":"Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients","volume":"68","author":"Shirali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1681\/ASN.2006050418","article-title":"Involvement of drug-specific T cells in acute drug-induced interstitial nephritis","volume":"17","author":"Spanou","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2215\/CJN.01390118","article-title":"Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis","volume":"13","author":"Fernandez-Juarez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/sj.ki.5002776","article-title":"Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis","volume":"73","author":"Gonz\u00e1lez","year":"2008","journal-title":"Kidney Int"},{"key":"B24-20230821","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2215\/CJN.06480612","article-title":"Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge","volume":"8","author":"Pannu","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: A systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1136\/annrheumdis-2018-214336","article-title":"Immune checkpoint inhibitor rechallenge in patients with immune-related myositis","volume":"78","author":"Delyon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B28-20230821","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer [published online ahead of print June 6, 2019]","author":"Simonaggio","journal-title":"JAMA Oncol"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000152019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:56:36Z","timestamp":1786478196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000152019"}},"subtitle":["Single Center Experience of Management and Drug Rechallenge"],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000152019","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}